Exploratory biomarker analyses were conducted to assess associations between response to sotorasib therapy, baseline tumor PD-L1 expression level, tumor mutational burden, and mutations in STK11, KEAP1, and TP53, which are among the most prevalent genes with co-occurring mutations in KRAS-mutated NSCLC [110]. Here, KRAS is linked to neoplasm.